INSM: SEC Form 3 filed by Insmed Incorporated
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for INSM
Across the 30 sessions after earlier INSM headlines, the stock closed higher 18 times and lower 12 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INSM | SPY |
|---|---|---|---|
| Oct 19, 2026 | Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan | -1.0% | +0.4% |
| Oct 14, 2026 | Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 | +1.0% | -1.1% |
| Oct 12, 2026 | Insmed downgraded by Wolfe Research | -2.0% | -0.1% |
| Oct 5, 2026 | Insmed Announces CFO Transition | -6.6% | +0.7% |
| Sep 24, 2026 | Goldman resumed coverage on Insmed with a new price target | +2.7% | -0.1% |
| Sep 21, 2026 | FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 | +0.8% | +1.6% |
Quantisnow market dataNASDAQ
INSM
Insmed Incorporated
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for INSM
Full INSM profile on Quantisnow Follow INSM and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time